GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Scaled Net Operating Assets

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Scaled Net Operating Assets : 0.72 (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Laboratorios Farmaceuticos Rovi's operating assets for the quarter that ended in Jun. 2024 was €812.7 Mil. Laboratorios Farmaceuticos Rovi's operating liabilities for the quarter that ended in Jun. 2024 was €253.4 Mil. Laboratorios Farmaceuticos Rovi's Total Assets for the quarter that ended in Mar. 2024 was €778.7 Mil. Therefore, Laboratorios Farmaceuticos Rovi's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.72.


Laboratorios Farmaceuticos Rovi Scaled Net Operating Assets Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Scaled Net Operating Assets Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.77 0.78 0.64 0.66

Laboratorios Farmaceuticos Rovi Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.70 0.74 0.72 -

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets falls into.



Laboratorios Farmaceuticos Rovi Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(774.562-190.963)/878.703
=0.66

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=799.884 - 25.322
=774.562

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=256.39 - 52.242 - 13.185
=190.963

Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Mar. 2024 )
=(812.747-253.404)/778.663
=0.72

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=857.325 - 44.578
=812.747

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=374.563 - 98.144 - 23.015
=253.404

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi Headlines

From GuruFocus

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 01-05-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 44,145 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Pluto TV Partners With TiVo to Expand the TiVo+ Content Network

By Business Wire Business Wire 05-05-2020